Hyperbilirubinemia is a condition in which too much bilirubin builds up in the blood, and it is overwhelmingly common in newborns while being far less frequent in adults. Bilirubin is the yellow pigment left over when old red blood cells break down, and when the body cannot clear it fast enough, levels rise and the skin and eyes turn yellow, a visible sign most people know as jaundice. The condition ranges from a harmless quirk of newborn physiology to a medical emergency that can damage the brain, depending on how high levels climb, how quickly they rise, and whether the bilirubin is in its processed or unprocessed form.
Where Bilirubin Comes From and How the Body Clears It
Your body constantly recycles red blood cells. When old cells are dismantled, an enzyme called heme oxygenase splits the heme molecule and releases biliverdin, which is quickly converted to bilirubin. This freshly made bilirubin is fat-soluble and not yet water-friendly, so it hitches a ride on albumin in the bloodstream to reach the liver. Once there, liver enzymes attach sugar molecules to it in a step called conjugation, turning it into a water-soluble form that can be dumped into bile and sent to the intestines. Gut bacteria further break it down into compounds called urobilinoids, which are eventually reduced to stercobilin, the pigment that gives stool its brown color, while a small fraction gets reabsorbed back into the blood and excreted by the kidneys.1PubMed Central. Bilirubin in the Liver-Gut Signaling Axis
Hyperbilirubinemia happens when any step in that chain gets overwhelmed or breaks down. If too many red blood cells are destroyed too fast, the liver cannot conjugate all the bilirubin flooding in. If the liver’s conjugation enzymes are missing or sluggish, unconjugated bilirubin accumulates. And if the bile ducts are blocked or the liver’s export machinery is faulty, conjugated bilirubin backs up into the bloodstream. Which type of bilirubin is elevated, unconjugated (indirect) or conjugated (direct), tells clinicians where the problem lies.
Why Almost Every Newborn Gets a Bump in Bilirubin
Unconjugated hyperbilirubinemia is common in the first week of life but rare after that. Newborns arrive with a high red-blood-cell count that served them well in the womb, and those extra cells start breaking down almost immediately after birth. At the same time, the newborn liver is still maturing, so its conjugation capacity lags behind the bilirubin load. Several other variables pile on: feeding patterns, ethnicity, and genetic variants at multiple metabolic steps can all push bilirubin higher than expected during those first days.2PubMed Central. Molecular Physiology and Pathophysiology of Bilirubin Handling by the Blood, Liver, Intestine, and Brain in the Newborn
Breastfeeding adds its own wrinkles. Two distinct patterns of jaundice are associated with nursing. The first is early-onset breastfeeding jaundice, which shows up in the first few days and is tied to insufficient caloric intake or infrequent feeds: when the baby does not eat enough, less bilirubin moves through the gut, and more gets reabsorbed back into the bloodstream. The second type appears later, typically after the first week, and lasts longer. Known as breast milk jaundice syndrome, it appears related to substances in the milk itself that slow bilirubin clearance.3PubMed. Breastfeeding and breast milk jaundice Most cases of both types resolve on their own, but they can be alarming for new parents who see their baby turning progressively yellower.
Hemolytic conditions, where red blood cells are destroyed faster than normal, represent a more urgent cause. Blood-type incompatibilities between mother and baby (such as ABO or Rh mismatch) can trigger the immune system to attack the infant’s red cells, releasing a surge of bilirubin.4PubMed Central. Neonatal Hemolytic Jaundice: Causes, Diagnostic Approach, and Management Non-immune causes, including inherited red-cell membrane defects and enzyme deficiencies, belong in the same category. These hemolytic cases require closer monitoring because bilirubin can climb fast.
When Bilirubin Becomes Dangerous
The fear around neonatal hyperbilirubinemia centers on a condition called kernicterus, in which unconjugated bilirubin crosses into the brain and damages neurons. Because unconjugated bilirubin is fat-soluble, it can slip through the blood-brain barrier, especially in premature infants whose barrier is less mature. Once inside, high concentrations disrupt cell membranes, cause energy failure in mitochondria, and trigger a cascade that includes rising calcium levels inside neurons. Those downstream events can activate cell-death pathways, leading to permanent damage or destruction of brain tissue.5PubMed. Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns
Kernicterus can cause hearing loss, abnormal muscle tone, intellectual disability, and a characteristic pattern of movement problems. The severity depends on both the peak bilirubin level and how long the exposure lasts. This is why hospitals screen every newborn and why, in severe cases, treatment is started urgently rather than waiting to see if levels come down on their own.
How Hospitals Screen and Track Bilirubin
Most nurseries now use transcutaneous bilirubinometers, handheld devices pressed against the baby’s skin that estimate bilirubin levels from the reflected light. A Cochrane review covering multiple devices found that these skin-based readings have high sensitivity for ruling out significant hyperbilirubinemia, with sensitivity ranging from 74% to 100% depending on the cutoff used. When a transcutaneous reading comes back high, it gets confirmed with a blood draw.6PubMed Central. Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns
The devices are not perfect. A large study found that the average difference between transcutaneous and serum measurements was modest, but in African American newborns, the gap was about 0.67 mg/dL larger than in other groups. The discrepancy also varied by meter brand and the baby’s age in hours. In roughly 2% of paired readings, the skin device underestimated the true serum level by 3 mg/dL or more.7PubMed Central. Discrepancies between transcutaneous and serum bilirubin measurements For this reason, transcutaneous readings are treated as screening tools, not definitive tests. Any borderline or high result triggers a blood sample.
Once a serum bilirubin level is in hand, clinicians plot it against the baby’s age in hours on a nomogram, a chart that divides newborns into risk zones. The original version of this nomogram was developed in 1999, and an updated version based on roughly 140 times the original number of subjects is now in use across major health systems.8PubMed. A New Hour-Specific Serum Bilirubin Nomogram for Neonates ≥35 Weeks of Gestation The nomogram helps clinicians decide whether an infant can safely go home, needs closer follow-up, or needs treatment right away. It has also been validated in infants with positive direct Coombs tests from blood-type incompatibility, meaning it works even when there is an immune-mediated reason for faster red-cell breakdown.9JAMA Pediatrics. Hour-Specific Bilirubin Nomogram in Infants With ABO Incompatibility and Direct Coombs-Positive Results
Emerging research suggests that measuring unbound (“free”) bilirubin, the fraction not attached to albumin, may be better at predicting brain toxicity than the total serum number alone. The rationale is straightforward: it is the unbound fraction that actually crosses into cells and does damage. While early studies look promising, especially in premature infants, no widely available clinical assay exists yet for free bilirubin.10PubMed Central. Newborn jaundice technologies: unbound bilirubin and bilirubin binding capacity in neonates
Treatment of Neonatal Hyperbilirubinemia
Phototherapy, placing the infant under special lights, remains the workhorse treatment and has been for about 60 years. The breakthrough came from a serendipitous observation that sunlight exposure lowered bilirubin levels. Modern phototherapy uses narrow-band blue LED light in the 450 to 470 nm range, which overlaps the peak absorption wavelength for bilirubin and converts it into water-soluble photoisomers the body can excrete without needing liver conjugation.11PubMed. Sixty years of phototherapy for neonatal jaundice – from serendipitous observation to standardized treatment and rescue for millions Across large datasets, roughly 80 to 88% of infants diagnosed with immune-related hemolytic jaundice receive phototherapy as their primary treatment.12PubMed Central. Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
When phototherapy alone is not enough, especially in immune-mediated hemolysis, clinicians may add intravenous immunoglobulin (IVIG), which helps slow the destruction of red blood cells. Use of IVIG rose from about 1% to 2% of affected infants between 2014 and 2018 in one large study, while exchange transfusion, a procedure in which the baby’s blood is partially replaced, dropped slightly over the same period and remained very rare at around 0.1 to 0.2%.13PubMed Central. Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia Exchange transfusion is reserved for the most severe cases when bilirubin levels keep climbing despite intensive phototherapy and IVIG.
Interestingly, the specific wavelength and type of light source matters more than you might expect. A study comparing blue LED devices with green fluorescent lamps in preterm infants found that the green lamps produced significantly higher urinary excretion of lumirubin per unit of light intensity, suggesting that the broader-spectrum light may have some advantages in specific settings.14Scientific Reports. Urinary lumirubin excretion in jaundiced preterm neonates during phototherapy with blue light-emitting diode vs. green fluorescent lamp Blue LEDs remain the standard, though, because they deliver high irradiance efficiently and are more practical in busy nurseries.
Inherited Conditions That Cause Chronic Hyperbilirubinemia
Beyond the transient jaundice of newborns, several genetic conditions can cause bilirubin to stay elevated for life. They fall into two broad groups based on whether the problem is with conjugation or with transport.
On the unconjugated side, Crigler-Najjar syndrome and Gilbert syndrome both arise from mutations in the UGT1A1 gene, the gene encoding the enzyme that conjugates bilirubin in the liver. They sit on a spectrum of severity.15PubMed Central. Between Crigler-Najjar Syndrome Type II and Gilbert Syndrome: Expanding the Spectrum of Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1)-Related Hyperbilirubinemia Crigler-Najjar type 1 sits at the severe end, with a complete absence of enzyme activity and dangerously high bilirubin levels that require daily phototherapy or liver transplantation. Type 2 retains some enzyme function and responds to certain medications that boost conjugation. Gilbert syndrome, the mildest form, involves only a partial reduction in enzyme activity and affects roughly 5 to 10% of some populations.16PubMed. UGT1A1 gene mutations in Pakistani children suffering from inherited nonhemolytic unconjugated hyperbilirubinemias People with Gilbert syndrome typically only notice jaundice during stress, fasting, or illness. Most never need treatment.
The genetics are worth noting because they are not as binary as a simple “you have it or you don’t” story. For Gilbert syndrome, homozygosity for a variant promoter sequence is necessary but not sufficient for visible jaundice; actual bilirubin levels also depend on the rate of bilirubin production. And some structural mutations of UGT1A1 cause mild reductions in enzyme activity that result in Gilbert-like hyperbilirubinemia through a different genetic mechanism entirely.17Human Mutation. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes This means that two people diagnosed with “Gilbert syndrome” may carry quite different mutations.
On the conjugated side, Dubin-Johnson syndrome and Rotor syndrome both cause conjugated hyperbilirubinemia, meaning the liver conjugates bilirubin just fine but cannot export it properly. Dubin-Johnson syndrome results from mutations in the MRP2 transporter, which pumps conjugated bilirubin into the bile ducts. Rotor syndrome arises from simultaneous mutations affecting two sinusoidal uptake transporters, OATP1B1 and OATP1B3, which impair the liver’s ability to recapture conjugated bilirubin from the blood.18PubMed Central. Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review Both conditions are benign; the jaundice is cosmetically noticeable but harmless.19Journal of Clinical and Translational Hepatology. Dubin-Johnson and Rotor Syndromes: A Review and Update of Pathophysiological Mechanisms
Hyperbilirubinemia in Adults
When jaundice shows up in an adult, the diagnostic thinking shifts considerably. Conjugated hyperbilirubinemia in adults usually signals real liver trouble or a blocked bile duct. Parenchymal liver disease (hepatitis, cirrhosis, drug toxicity) and biliary obstruction (gallstones, tumors pressing on the common bile duct) are the most common culprits, and the presence of conjugated hyperbilirubinemia generally prompts imaging and further workup.20American Journal of Gastroenterology. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries – Section: Elevation of total bilirubin level
Unconjugated hyperbilirubinemia in adults is less common. Gilbert syndrome accounts for most mild cases. When bilirubin levels are higher than Gilbert syndrome would explain, clinicians look for hemolytic anemias, where red cells are being destroyed faster than normal. An interesting clinical overlap occurs when someone has both an inherited hemolytic anemia and Gilbert syndrome: the hemolysis provides a high bilirubin load, and the sluggish UGT1A1 enzyme cannot keep up, producing bilirubin levels that seem disproportionate to the degree of anemia. Multiple case reports have documented this “double hit” pattern.21Pediatric Hematology Oncology Journal. Gilbert syndrome in patients with inherited hemolytic anemia modifies the clinical phenotype
Medications can also raise unconjugated bilirubin. Certain drugs inhibit OATP1B1, the same transporter affected in Rotor syndrome, which slows the liver’s uptake of bilirubin from the blood. This mechanism has been identified as an important cause of drug-induced unconjugated hyperbilirubinemia, and it occasionally shows up in clinical trials as an adverse-event signal for new medications.22PubMed. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia The anti-HIV drug atazanavir, for instance, is well known for causing jaundice through UGT1A1 inhibition, essentially giving patients a pharmacological version of Gilbert syndrome.
The Paradox of Mildly Elevated Bilirubin
One of the more counterintuitive findings in cardiovascular research is that people with slightly elevated bilirubin levels seem to have lower rates of heart disease. A large longitudinal study found that people in the highest tertile of bilirubin had significantly lower risks of coronary heart disease and cardiovascular death compared with those in the lowest tertile, even after adjusting for standard risk factors.23PubMed Central. Relationship between serum bilirubin levels and cardiovascular disease A meta-analysis pooling data from 12 population-based studies found a pooled risk reduction of about 7% for cardiovascular disease per standard-deviation increase in total bilirubin.24PubMed. Circulating total bilirubin and risk of incident cardiovascular disease in the general population
The likely explanation lies in bilirubin’s role as an antioxidant. Unconjugated bilirubin is fat-soluble, and it turns out to be remarkably good at protecting lipids from oxidation. In laboratory experiments, bilirubin accumulating inside cells reduced lipid damage in a dose-dependent manner.25PubMed. Intracellular accumulation of bilirubin as a defense mechanism against increased oxidative stress The body appears to have a division of labor: the water-soluble antioxidant glutathione handles proteins, while fat-soluble bilirubin guards lipids. When the enzyme that produces biliverdin (the precursor to bilirubin) is knocked out in mice, lipid oxidation rises disproportionately compared to protein oxidation.26PubMed Central. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles On top of the direct scavenging, bilirubin dampens inflammatory signaling pathways, which may further explain its links to lower cardiovascular risk and potentially to protection against metabolic and neurodegenerative conditions.27International Journal of Clinical Biochemistry and Research. Bilirubin as an antioxidant marker
This creates a genuine paradox: a molecule that can destroy a newborn’s brain at high concentrations appears to protect adult cardiovascular health at mildly elevated levels. People with Gilbert syndrome, whose bilirubin runs chronically above normal, seem to be inadvertent beneficiaries. The relationship is dose-dependent and nonlinear, though, and nobody is suggesting that inducing jaundice is a good idea. The protective window is narrow, and it sits well below the threshold where bilirubin starts doing harm.
Bilirubin Beyond Humans
Not all animals handle bilirubin the same way. Most mammals, including humans, convert biliverdin all the way to bilirubin, while birds, reptiles, and many fish stop at the green-pigmented biliverdin stage and excrete that instead. One hypothesis for why mammals evolved to take the extra step relates to the gut. Deconjugated bilirubin potently inhibits digestive enzymes: at physiological concentrations, it blocks trypsin activity by up to 80% and pepsin activity by up to 50%.28PubMed Central. Inactivation of digestive proteases by deconjugated bilirubin: the possible evolutionary driving force for bilirubin or biliverdin predominance in animals This protease-inhibiting effect could serve as a brake that prevents the gut from digesting itself, or it could help regulate how efficiently dietary protein is broken down. The fact that biliverdin lacks this property may explain why evolution conserved the extra enzymatic step in species that rely heavily on proteolytic digestion.
This comparative angle also illuminates why bilirubin metabolism is so tightly regulated. The molecule has real biological utility at low concentrations, both as an antioxidant and as a digestive modulator, but its toxicity at high concentrations means the body cannot simply let levels drift upward. The elaborate conjugation and export machinery in the liver exists to keep bilirubin within a useful range, and almost every form of hyperbilirubinemia represents some breakdown in that carefully balanced system.